Biobetters 市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

2023 年，全球 Biobetters 市场估值为 528 亿美元，由于癌症、糖尿病和自体免疫疾病等慢性疾病的盛行率不断上升，2024 年至 2032 年期间复合年增长率将达到 8.3%。随着这些病症变得越来越普遍，对可提高疗效并改善患者预后的先进治疗的需求不断增加。生物技术的创新，包括蛋白质工程和药物传递系统的进步，使得能够开发出与现有生物製剂相比具有更优越治疗效果的生物改良剂。不断增长的医疗需求和技术进步的结合将推动市场扩张。

生物改良剂产业根据药物类别、应用、给药途径、配销通路和地区进行分类。

凭藉其巨大的治疗潜力和广泛的应用，单株抗体 Biobetter 细分市场到 2023 年将获得 385 亿美元的收入。单株抗体对于治疗各种疾病至关重要，包括癌症和自体免疫疾病。这些抗体的改进版本提供了更高的功效、更长的半衰期和更少的副作用，从而推动了它们的需求。随着市场不断扩大，重点开发更有效、更有针对性的单株抗体疗法将巩固该领域的主导地位。

2023 年，医院药局部门的销售额为 252 亿美元，主要是因为它们在管理复杂的生物治疗方面发挥核心作用。医院药局配备齐全，可满足单株抗体和其他先进疗法等生物改良剂的专门储存和处理要求。此外，这些设施对于管理患者特定剂量和为药物管理提供专家支援至关重要。随着生物改良剂使用的增长，医院药房将继续成为关键部分，以支持这些先进治疗方法的分配和优化使用。

由于其先进的医疗基础设施、慢性病的高盛行率以及对生物技术创新的高度重视，到 2032 年，北美生物改良剂市场将产生 441 亿美元的收入。该地区成熟的製药业和充足的研发投资有助于生物改良剂的开发和采用。此外，有利的监管环境和高医疗保健支出进一步推动市场成长。随着北美在技术进步和治疗创新方面继续领先，它仍然是生物改良剂行业的关键贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 增强治疗效果并减少副作用
    • 慢性病盛行率上升
    • 不断增加对生物改良剂研发的投资
  • 产业陷阱与挑战
    • 开发成本高
    • 严格的监管场景
• 成长潜力分析
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 未来市场趋势
• 差距分析
• 波特的分析
• 杵分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 促红血球生成素生物改善剂
• 胰岛素生物改善剂
• G-CSF生物改良剂
• 单株抗体生物改良剂
• 抗血友病因子
• 其他药物类别

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 癌症
• 糖尿病
• 肾臟疾病
• 神经退化性疾病
• 遗传性疾病
• 其他应用

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 皮下
• 静脉
• 其他给药途径

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion Inc.
• Eli Lilly And Company
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Kiniksa Pharmaceuticals, Ltd.
• Merck and Co., Inc.
• Novo Nordisk A/S
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited

The Global Biobetters Market was valued at USD 52.8 billion in 2023 and will grow at an 8.3% CAGR between 2024 and 2032, attributed to the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. As these conditions become more common, there is an increased demand for advanced treatments that offer enhanced efficacy and improved patient outcomes. Innovations in biotechnology, including advancements in protein engineering and drug delivery systems, enable the development of biobetters with superior therapeutic profiles compared to existing biologics. This combination of growing medical needs and technological progress will propel the market expansion.

The biobetters industry is segregated on the basis of drug class, application, route of administration, distribution channel, and region.

The monoclonal antibodies biobetters segment garnered USD 38.5 billion in 2023, propelled by their significant therapeutic potential and widespread use. Monoclonal antibodies are crucial in treating various diseases, including cancers and autoimmune disorders. Improved versions of these antibodies offer enhanced efficacy, a longer half-life, and reduced side effects, which drive their demand. As the market continues to expand, the focus on developing more effective and targeted monoclonal antibody therapies will reinforce this segment's dominance.

The hospital pharmacies segment held USD 25.2 billion in 2023, primarily due to their central role in administering complex biological treatments. Hospital pharmacies are equipped to handle the specialized storage and handling requirements of biobetters, such as monoclonal antibodies and other advanced therapies. Additionally, these facilities are crucial for managing patient-specific dosing and providing expert support for drug administration. As the use of biobetters grows, hospital pharmacies will continue to be a key segment, supporting the distribution and optimal use of these advanced treatments.

North America biobetters market will generate USD 44.1 billion by 2032 due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and strong focus on biotechnology innovation. The region's well-established pharmaceutical industry and ample investment in research and development contribute to the development and adoption of biobetters. Besides, favorable regulatory environments and high healthcare spending further drive market growth. As North America continues to lead in technological advancements and therapeutic innovations, it remains a key contributor to the biobetters industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Enhanced therapeutic effectiveness and reduced side effects
    • 3.2.1.2 Rising prevalence of chronic disease
    • 3.2.1.3 Growing investment in research and development of biobetters
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTLE analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Erythropoietin biobetters
• 5.3 Insulin biobetters
• 5.4 G-CSF biobetters
• 5.5 Monoclonal antibodies biobetters
• 5.6 Antihemophilic factor
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
• 6.3 Diabetes
• 6.4 Renal disease
• 6.5 Neurodegenerative disease
• 6.6 Genetic disorders
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Subcutaneous
• 7.3 Intravenous
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 AstraZeneca PLC
• 10.4 Biogen Inc.
• 10.5 Bristol-Myers Squibb Company
• 10.6 Celltrion Inc.
• 10.7 Eli Lilly And Company
• 10.8 F. Hoffmann-La Roche Ltd.
• 10.9 GSK plc
• 10.10 Kiniksa Pharmaceuticals, Ltd.
• 10.11 Merck and Co., Inc.
• 10.12 Novo Nordisk A/S
• 10.13 Regeneron Pharmaceuticals, Inc.
• 10.14 Sanofi
• 10.15 Teva Pharmaceutical Industries Limited